TCRX
Price:
$3.01
Market Cap:
$160.65M
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients ...[Read more]
Industry
Biotechnology
IPO Date
2021-07-16
Stock Exchange
NASDAQ
Ticker
TCRX
According to TScan Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 117.88M. This represents a change of -79.44% compared to the average of 573.27M of the last 4 quarters.
The mean historical Enterprise Value of TScan Therapeutics, Inc. over the last ten years is 151.29M. The current 117.88M Enterprise Value has changed 7.69% with respect to the historical average. Over the past ten years (40 quarters), TCRX's Enterprise Value was at its highest in in the March 2024 quarter at 711.21M. The Enterprise Value was at its lowest in in the March 2022 quarter at -68063002.40.
Average
151.29M
Median
224.98M
Minimum
-47777813.50
Maximum
341.52M
Discovering the peaks and valleys of TScan Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 10.47%
Maximum Annual Enterprise Value = 341.52M
Minimum Annual Increase = -120.37%
Minimum Annual Enterprise Value = -47777813.50
Year | Enterprise Value | Change |
---|---|---|
2023 | 341.52M | 10.47% |
2022 | 3.23M | -106.76% |
2021 | -47777813.50 | -120.37% |
2020 | 234.50M | 4.23% |
The current Enterprise Value of TScan Therapeutics, Inc. (TCRX) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
98.99M
5-year avg
151.29M
10-year avg
151.29M
TScan Therapeutics, Inc.’s Enterprise Value is less than VectivBio Holding AG (848.58M), less than Icosavax, Inc. (713.87M), less than Apellis Pharmaceuticals, Inc. (4.20B), less than iTeos Therapeutics, Inc. (150.31M), less than Day One Biopharmaceuticals, Inc. (859.59M), greater than Acumen Pharmaceuticals, Inc. (103.15M), greater than X4 Pharmaceuticals, Inc. (79.21M), less than Inozyme Pharma, Inc. (215.58M), greater than Cognition Therapeutics, Inc. (4.08M), greater than TFF Pharmaceuticals, Inc. (-2265301.00), greater than Cue Biopharma, Inc. (42.98M), greater than Dermata Therapeutics, Inc. (-3633607.00), less than ProQR Therapeutics N.V. (192.77M), less than Annexon, Inc. (512.88M), less than Arrowhead Pharmaceuticals, Inc. (2.87B), less than Terns Pharmaceuticals, Inc. (234.86M),
Company | Enterprise Value | Market cap |
---|---|---|
848.58M | $1.06B | |
713.87M | $769.04M | |
4.20B | $4.13B | |
150.31M | $268.52M | |
859.59M | $1.28B | |
103.15M | $106.34M | |
79.21M | $98.42M | |
215.58M | $193.36M | |
4.08M | $25.51M | |
-2265301.00 | $288.80K | |
42.98M | $65.88M | |
-3633607.00 | $2.51M | |
192.77M | $275.55M | |
512.88M | $562.82M | |
2.87B | $2.46B | |
234.86M | $503.69M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like TScan Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like TScan Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is TScan Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for TScan Therapeutics, Inc. (TCRX)?
What is the 3-year average Enterprise Value for TScan Therapeutics, Inc. (TCRX)?
What is the 5-year average Enterprise Value for TScan Therapeutics, Inc. (TCRX)?
How does the current Enterprise Value for TScan Therapeutics, Inc. (TCRX) compare to its historical average?